Retatrutide clinical trial timeline 2026 — TRIUMPH program Phase 3 results, TRANSCEND-T2D-1, TRIUMPH-1 outcomes, and LY3437943 regulatory outlook.

Retatrutide Clinical Trial Timeline: The Complete TRIUMPH Program Guide (2026 Update)

Retatrutide (LY3437943) has one of the most closely watched clinical development programs in modern metabolic pharmacology. Since its Phase 1 studies in 2020-2021, the compound has progressed through an ambitious clinical program that includes the ongoing TRIUMPH Phase 3 trial series and multiple parallel investigations across obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and other research applications. Understanding the retatrutide clinical trial timeline — where the compound has been and where it's going — is essential context for researchers, informed observers, and anyone tracking the incretin research landscape.

This guide provides a comprehensive retatrutide clinical trial timeline from Phase 1 through the most recent Phase 3 readouts in 2026, plus the anticipated regulatory pathway. Whether you're evaluating Retatrutide research peptide in the context of its clinical development or tracking the compound's trajectory for research purposes, this guide covers what you need to know.

The short version: Retatrutide's clinical program began with Phase 1 safety studies in 2020-2021, advanced through Phase 2 obesity trials with landmark results published in the New England Journal of Medicine in 2023, and entered Phase 3 development with the TRIUMPH program in 2023-2024. As of mid-2026, three pivotal Phase 3 readouts have been reported: TRIUMPH-4 (December 2025) showing 28.7% mean body weight reduction at 68 weeks in obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) showing A1C reductions up to 2.0% and weight loss up to 16.8% at 40 weeks in type 2 diabetes, and TRIUMPH-1 (May 2026) showing up to 25.0% body weight reduction at 80 weeks in obesity. Seven additional Phase 3 readouts are expected before the end of 2026, with NDA submission anticipated Q4 2026 to Q1 2027 and potential FDA approval in late 2027 to 2028. The long version explains each phase of the timeline in detail.

Table of Contents

Retatrutide Clinical Timeline at a Glance

Phase Trial Year Key Result
Phase 1 Single ascending dose (Singapore) 2020-2021 Safety profile established; once-weekly PK confirmed
Phase 1b Multiple ascending dose in T2D 2021-2022 Published in The Lancet 2022
Phase 2 Obesity Phase 2 (48-week) 2022-2023 ~24% body weight reduction; published NEJM 2023
Phase 3 TRIUMPH-4 (obesity + osteoarthritis) December 2025 28.7% weight reduction at 68 weeks (12mg)
Phase 3 TRANSCEND-T2D-1 (T2D) March 2026 A1C reduction up to 2.0%; 16.8% weight loss at 40 weeks
Phase 3 TRIUMPH-1 (pivotal obesity) May 2026 25.0% weight reduction at 80 weeks (12mg)
Phase 3 Additional TRIUMPH readouts Late 2026 7 additional Phase 3 readouts expected
Regulatory NDA submission (estimated) Q4 2026-Q1 2027 Based on Lilly's disclosed timeline
Regulatory Potential FDA approval Late 2027-2028 10-12 month standard review timeline

Phase 1 Development (2020-2021)

Retatrutide's clinical development began with Phase 1 safety and pharmacokinetic studies that established the compound's basic profile.

Single Ascending Dose Study (Singapore)

The first Phase 1 trial was a single ascending dose study conducted in Singapore, involving 47 healthy participants who received retatrutide or placebo. The study, published by Coskun and colleagues, established several critical characteristics that would define subsequent clinical development:

  • Safety profile: Initial safety assessment across escalating single doses
  • Pharmacokinetic profile: Established the compound's extended half-life
  • Dosing frequency confirmation: Confirmed pharmacokinetics supported once-weekly administration
  • Baseline pharmacodynamic effects: Preliminary observations of glucose and metabolic effects

Phase 1b Multiple Ascending Dose Study

The Phase 1b trial was published in The Lancet in 2022 (Urva, Coskun, Loh et al., Volume 400, pp. 1869-1881), as a multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose study in people with type 2 diabetes. This trial:

  • Extended safety assessment across multiple ascending doses over weeks
  • Provided initial efficacy signals in the type 2 diabetes population
  • Confirmed the pharmacokinetic profile supported weekly dosing at higher doses
  • Generated the preliminary metabolic effect data that supported Phase 2 progression

The Phase 1b publication in The Lancet in 2022 represented the first major peer-reviewed publication for the compound and generated substantial research community interest.

Phase 2 Development (2021-2023)

Retatrutide's Phase 2 program produced the landmark results that positioned the compound as one of the most-watched developments in metabolic pharmacology.

Phase 2 Obesity Trial

The pivotal Phase 2 obesity trial evaluated Retatrutide across multiple dose levels in participants with obesity but without type 2 diabetes. Key characteristics of the trial:

  • Duration: 48 weeks
  • Design: Randomized, double-blind, placebo-controlled
  • Doses: Multiple dose levels including up to 12mg weekly
  • Primary endpoint: Percentage body weight change from baseline at 48 weeks

Phase 2 Results (Published NEJM 2023)

The Phase 2 results were published in the New England Journal of Medicine in 2023, generating substantial coverage across the metabolic research community. Key findings included:

  • Dose-dependent body weight reductions reaching approximately 24% at highest doses at 48 weeks
  • HbA1c improvements in participants with prediabetes
  • Documented energy expenditure increases through indirect calorimetry
  • Favorable safety profile with side effects primarily related to gastrointestinal tolerability
  • No weight loss plateau observed within the 48-week trial period

Phase 2 Metabolic Effect Signals

Beyond weight and glycemic effects, the Phase 2 program identified additional signals that shaped subsequent Phase 3 program design:

  • 86% liver fat reduction at the 12mg dose, with 93% of participants achieving significant liver fat reduction
  • Cardiovascular risk factor improvements including LDL, triglycerides, and blood pressure
  • Prediabetes reversal signals in the metabolic risk population
  • Waist circumference reductions supporting adiposity effects

These Phase 2 signals justified the ambitious Phase 3 program that would investigate Retatrutide across multiple metabolic and metabolic-adjacent research applications. For deeper coverage of Retatrutide's mechanism, see How Does Retatrutide Work? Understanding Triple Hormone Receptor Agonists.

The TRIUMPH Phase 3 Program Overview

Eli Lilly's Phase 3 program for Retatrutide is called TRIUMPH — an acronym for the trial series investigating the compound across multiple applications.

TRIUMPH Program Structure

The TRIUMPH program includes multiple Phase 3 trials investigating Retatrutide across:

  • Obesity (primary indication): TRIUMPH-1 and related trials
  • Type 2 diabetes: TRANSCEND-T2D-1 and TRIUMPH-2
  • Obesity with comorbidities: TRIUMPH-4 (knee osteoarthritis)
  • MASLD (metabolic dysfunction-associated steatotic liver disease): Dedicated Phase 3 investigation
  • Chronic low back pain: Extending investigation to pain-related applications
  • Maintenance dosing strategies: Long-term dosing optimization

TRIUMPH Design Principles

Common design features across TRIUMPH trials include:

  • Once-weekly subcutaneous administration
  • Multiple dose arms (typically including 4mg, 9mg, and 12mg weekly doses)
  • Placebo-controlled randomization
  • Extended treatment durations (68-80 weeks in most trials)
  • Primary endpoints focused on percentage body weight change or glycemic control
  • Comprehensive secondary endpoint panels covering cardiovascular risk factors

Program Timeline

The TRIUMPH program has progressed from initial trial launches in 2023-2024 through the readout period that began December 2025 and continues through 2026. Seven additional Phase 3 readouts are expected before the end of 2026, making 2026 a defining year for the compound's clinical evidence base.

TRIUMPH-4: Obesity with Knee Osteoarthritis (December 2025)

TRIUMPH-4 was the first successful Phase 3 readout for Retatrutide, providing the initial confirmation of the compound's Phase 3 efficacy.

Trial Design

TRIUMPH-4 was a 68-week, randomized, double-blind, placebo-controlled trial in 445 adults with obesity or overweight and knee osteoarthritis, without diabetes. The trial's design:

  • Duration: 68 weeks
  • Population: Adults with obesity or overweight + knee osteoarthritis, without diabetes
  • Enrollment: 445 participants
  • Design: Randomized, double-blind, placebo-controlled
  • Doses: Multiple dose arms including 9mg and 12mg

TRIUMPH-4 Results (December 2025)

The trial reported 28.7% mean body weight reduction at 68 weeks on the 12mg weekly dose (26.4% on 9mg, 2.1% on placebo). Additional findings included:

  • 28.7% mean body weight reduction on 12mg dose (compared to 2.1% on placebo)
  • 26.4% mean body weight reduction on 9mg dose
  • Metabolic secondary endpoint improvements
  • Potential effects on osteoarthritis-related pain measures

TRIUMPH-4 Significance

TRIUMPH-4's results were significant beyond just confirming Phase 2-observed efficacy. The trial's population (obesity with knee osteoarthritis) represented a research question distinct from pure obesity, and the results suggested Retatrutide might have applications extending beyond the core obesity indication. The metabolic secondary endpoint signals distinguished retatrutide from other compounds in the class.

TRANSCEND-T2D-1: Type 2 Diabetes (March 2026)

The second major Phase 3 readout — TRANSCEND-T2D-1 — provided the compound's first Phase 3 efficacy data in the type 2 diabetes population.

Trial Design

TRANSCEND-T2D-1 was a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide as an adjunct to diet and exercise. The trial enrolled adults diagnosed with type 2 diabetes with inadequate glycemic control with diet and exercise alone, and a mean duration of diabetes of 2.5 years. Key trial characteristics:

  • Duration: 40 weeks
  • Population: Adults with T2D, inadequate glycemic control on diet and exercise alone
  • Design: Placebo-controlled, adjunct to diet and exercise
  • Primary endpoint: A1C reduction from baseline

TRANSCEND-T2D-1 Results (March 2026)

The trial met primary and all key secondary endpoints, delivering A1C reductions of up to 2.0% and average weight loss of up to 36.6 lbs (16.8%) on the 12 mg dose. Additional highlights:

  • A1C reductions up to 2.0% at 40 weeks
  • Weight loss up to 16.8% at 40 weeks (versus 40 weeks in T2D population — remarkable for the shorter duration)
  • All primary and key secondary endpoints met
  • No weight loss plateau observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeks

TRANSCEND-T2D-1 Significance

The TRANSCEND-T2D-1 results confirmed Retatrutide's efficacy extended to the type 2 diabetes population — critical for the compound's broader clinical application. The 2.0% A1C reduction represents a substantial glycemic effect, and the weight loss data at 40 weeks suggests the compound's metabolic effects extend meaningfully into the diabetic population.

TRIUMPH-1: Pivotal Obesity Trial (May 2026)

TRIUMPH-1 represents the largest and most pivotal Phase 3 readout for Retatrutide's core obesity indication.

Trial Design

TRIUMPH-1 involved 2,339 participants who were randomised to receive either retatrutide 4mg, 9mg, 12mg (building up every four weeks from 2mg), or placebo. Additional design elements:

  • Duration: 80 weeks
  • Enrollment: 2,339 participants
  • Population: Adults with obesity or overweight + at least one weight-related health condition, without diabetes
  • Design: Randomized, double-blind, placebo-controlled
  • Dose escalation: Building up every four weeks from 2mg to target dose
  • Dose arms: 4mg, 9mg, 12mg, or placebo

TRIUMPH-1 Results (May 21, 2026)

At 80 weeks, participants on 4mg of retatrutide lost an average of 17.6% of their body weight, compared with 23.7% on 9mg, 25.0% on 12mg and 3.9% on placebo. Additional findings:

  • 17.6% mean weight reduction at 4mg dose (80 weeks)
  • 23.7% mean weight reduction at 9mg dose (80 weeks)
  • 25.0% mean weight reduction at 12mg dose (80 weeks)
  • 3.9% weight reduction on placebo
  • 45.3% of patients on 12mg dose lost more than 30% of their body weight — an outcome commonly associated with weight loss surgery
  • 532 participants with BMI ≥35 at week 0, who had tolerated their assigned dose of medication, were then escalated to the maximum tolerated dose (9mg or 12mg) for a further 24 weeks
  • Cardiovascular risk factor improvements including LDL, triglycerides, blood pressure, waist circumference, non-HDL cholesterol, and hsCRP

TRIUMPH-1 Significance

TRIUMPH-1 was the pivotal trial for Retatrutide's core obesity indication and represents the largest efficacy dataset for the compound. The results confirmed meaningful weight loss at all doses in the largest Phase 3 trial to date. The 45.3% of participants achieving >30% body weight loss at the 12mg dose is a particularly notable finding — this level of weight loss has historically been associated with weight loss surgery rather than pharmacological interventions.

For extended dosing beyond 80 weeks with dose escalation, participants continued to lose weight, suggesting the compound's effects may extend beyond the primary trial period. For comparison across the incretin agonist class, see Retatrutide vs Tirzepatide vs Semaglutide: Complete Comparison.

Upcoming Phase 3 Readouts (Rest of 2026)

Beyond the three completed Phase 3 readouts, seven additional Phase 3 readouts are expected before the end of 2026.

Expected Readouts

The upcoming TRIUMPH program readouts include:

  • TRIUMPH-2: Additional type 2 diabetes investigation
  • MASLD-focused trials: Phase 3 investigation in metabolic dysfunction-associated steatotic liver disease
  • Chronic low back pain trials: Extending investigation to pain-related applications
  • Maintenance dosing studies: Long-term dosing strategies after initial weight loss
  • Additional obesity investigations: Various populations and durations

What These Readouts Will Establish

The upcoming readouts will address several important research questions:

  • Effect durability in longer-duration trials
  • Efficacy across broader populations and comorbidity contexts
  • MASLD effects that Phase 2 signals suggested might be substantial
  • Maintenance strategies for sustained weight loss
  • Additional safety data across longer treatment durations

The completion of these readouts in 2026 will provide the comprehensive evidence base necessary for regulatory submission and clinical decision-making.

Regulatory Pathway and Approval Outlook

The completion of the Phase 3 program sets the stage for Retatrutide's regulatory pathway.

NDA Submission Timeline

Eli Lilly's New Drug Application is expected in the Q4 2026 to Q1 2027 window. This timeline assumes:

  • Successful completion of the remaining Phase 3 readouts through 2026
  • Completion of manufacturing scale-up and validation
  • Preparation of the comprehensive NDA data package
  • Regulatory strategy alignment across major jurisdictions

FDA Approval Timeline

Assuming standard 10-12 month review, FDA approval is realistically a late 2027 to 2028 event. This assumes:

  • Standard review timeline without additional data requests
  • No safety signals requiring additional risk mitigation
  • Successful advisory committee proceedings if convened
  • Manufacturing site inspections completed on schedule

International Regulatory Timelines

Following FDA approval, international regulatory timelines typically follow:

  • UK MHRA: Typically 6-12 months after FDA approval (2027-2028)
  • European EMA: Similar timeframe to MHRA
  • Health Canada: Generally follows FDA timelines closely
  • Other jurisdictions: Timeframes vary by country

Commercial Considerations

Industry analyst GlobalData has forecast peak retatrutide sales of approximately $15.6 billion by 2031, contingent on Phase 3 program completion and timely approval. This forecast reflects the compound's potential position in the metabolic pharmaceutical market if the anticipated approval timeline materializes.

Important Caveats

No official regulatory timeline has been confirmed by Eli Lilly or any regulatory agency. These estimates are based on typical drug development timelines and analyst projections. Unexpected safety signals, manufacturing challenges, or regulatory requests for additional data could delay the timeline.

What This Means for Retatrutide Research Context

The clinical trial timeline substantially affects how researchers should understand Retatrutide's current position.

Current Regulatory Status

As of mid-2026, retatrutide is not approved by the FDA, is not approved by the EMA, and has no active approval in any major regulatory jurisdiction. It is an investigational compound under Phase 3 evaluation. This means:

  • Retatrutide cannot be legally prescribed for any indication
  • The compound is not available as a pharmaceutical product
  • Access is limited to clinical trial enrollment or research use only contexts
  • Research-grade Retatrutide is sold strictly for laboratory research use

Research Peptide Positioning

For research contexts, the Phase 3 program strengthens Retatrutide's positioning as a research peptide of substantial scientific interest. The compound has moved from Phase 2 promise to Phase 3-confirmed effects, making it one of the most scientifically well-characterized research peptides available for laboratory investigation of triple hormone receptor agonism.

Research Applications

Research applications for Retatrutide include:

  • Triple agonist pharmacology research: Investigating balanced multi-receptor engagement
  • Metabolic research: Investigating glucose, lipid, and energy metabolism interactions
  • Comparative agonist research: Comparing single, dual, and triple agonist mechanisms
  • Adiposity research: Investigating adipose tissue biology and fat metabolism
  • MASLD/hepatic research: Investigating hepatic fat metabolism effects

What Doesn't Change

The legal and regulatory framing of all current retatrutide use stays where it has always been. Research-use-only. Not for human consumption outside of a clinical trial. Not a substitute for approved therapy. The Phase 3 data makes the compound more interesting scientifically; it does not make it available clinically.

Sourcing Considerations

Researchers sourcing Retatrutide should look for suppliers meeting quality standards:

  • ≥99% HPLC purity confirmation on every batch
  • Mass spectrometry identity verification matching LY3437943's molecular weight
  • Batch-specific certificates of analysis
  • Domestic Canadian shipping for supply chain integrity

Emerald Peptides supplies Retatrutide research peptide for research use only, with all these quality standards. For comprehensive sourcing guidance, see our Retatrutide Buying Guide.

Frequently Asked Questions

What is the current status of Retatrutide clinical trials?

As of mid-2026, Retatrutide is in Phase 3 clinical development through the TRIUMPH program. Three pivotal Phase 3 readouts have been reported: TRIUMPH-4 (December 2025) showing 28.7% weight reduction at 68 weeks in obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) showing A1C reductions up to 2.0% and 16.8% weight loss at 40 weeks in type 2 diabetes, and TRIUMPH-1 (May 2026) showing up to 25.0% weight reduction at 80 weeks in the pivotal obesity trial. Seven additional Phase 3 readouts are expected before the end of 2026.

When will Retatrutide be FDA-approved?

Based on Eli Lilly's disclosed timeline, NDA (New Drug Application) submission is expected in the Q4 2026 to Q1 2027 window. Assuming standard 10-12 month FDA review, potential approval is realistically a late 2027 to 2028 event. However, no official regulatory timeline has been confirmed by Eli Lilly or the FDA. Unexpected safety signals, manufacturing challenges, or additional data requests could delay this timeline. As of mid-2026, Retatrutide remains investigational and is not approved for any indication.

What is the TRIUMPH program?

The TRIUMPH program is Eli Lilly's Phase 3 clinical trial series for Retatrutide, investigating the compound across multiple indications and populations. The program includes TRIUMPH-1 (pivotal obesity trial), TRIUMPH-2 (additional T2D), TRIUMPH-4 (obesity with knee osteoarthritis), TRANSCEND-T2D-1 (type 2 diabetes), and additional trials in MASLD, chronic low back pain, and maintenance dosing strategies. The program is designed to establish Retatrutide's evidence base across multiple metabolic and metabolic-adjacent research applications.

What were the TRIUMPH-1 results?

TRIUMPH-1 was the largest Phase 3 trial for Retatrutide, involving 2,339 participants over 80 weeks. At 80 weeks, participants on 4mg lost 17.6%, 9mg lost 23.7%, 12mg lost 25.0% of body weight, versus 3.9% on placebo. Notably, 45.3% of participants on the 12mg dose lost more than 30% of body weight — an outcome historically associated with weight loss surgery. The trial also showed improvements in cardiovascular risk factors including LDL, triglycerides, blood pressure, waist circumference, non-HDL cholesterol, and hsCRP.

What were the TRANSCEND-T2D-1 results?

TRANSCEND-T2D-1 was Retatrutide's Phase 3 trial in type 2 diabetes, running 40 weeks. The trial met all primary and key secondary endpoints, delivering A1C reductions of up to 2.0% and average weight loss of up to 16.8% (36.6 lbs) on the 12mg dose. Importantly, no weight loss plateau was observed, with participants continuing their weight loss trajectory through the 40-week trial period. This confirmed Retatrutide's efficacy extended to the type 2 diabetes population.

What were the TRIUMPH-4 results?

TRIUMPH-4 was the first successful Phase 3 readout for Retatrutide (December 2025). The 68-week trial in 445 adults with obesity or overweight and knee osteoarthritis reported 28.7% mean body weight reduction on the 12mg weekly dose, 26.4% on 9mg, and 2.1% on placebo. The trial's success confirmed the Phase 2-observed efficacy translated to Phase 3 with the added context of the osteoarthritis comorbidity population.

Where can I read the Retatrutide clinical trial results?

Peer-reviewed research on Retatrutide is searchable through PubMed retatrutide research. Clinical trial information is available through ClinicalTrials.gov retatrutide trials. Major peer-reviewed publications include the Phase 1b results in The Lancet (2022) and Phase 2 obesity results in the New England Journal of Medicine (2023). Eli Lilly publishes Phase 3 readouts through press releases and, subsequently, peer-reviewed publications.

Is Retatrutide legal to purchase?

Retatrutide is not approved for human use by Health Canada, the FDA, or any other regulatory agency as of mid-2026, meaning it cannot be legally prescribed for any indication. Research-grade Retatrutide is sold strictly for laboratory research use only, not for human consumption. Research peptide suppliers do not sell Retatrutide for therapeutic purposes. The compound remains in Phase 3 clinical evaluation, and any therapeutic use requires clinical trial enrollment.

How does the Retatrutide clinical timeline affect research decisions?

The advancing Phase 3 program strengthens Retatrutide's scientific evidence base substantially. Researchers now have access to Phase 3 confirmed efficacy data rather than relying solely on Phase 2 projections. This makes Retatrutide one of the most scientifically well-characterized research peptides available for laboratory investigation of triple hormone receptor agonism. Research designs benefit from the extensive published trial data supporting hypotheses about the compound's effects, mechanism, and pharmacokinetics.

Where can researchers buy Retatrutide in Canada?

Canadian research labs sourcing Retatrutide should look for suppliers meeting key quality criteria: ≥99% HPLC purity confirmation on every batch, mass spectrometry verification of identity matching LY3437943's molecular weight, batch-specific certificates of analysis, and domestic Canadian shipping. Emerald Peptides supplies Retatrutide research peptide for research use only, with all these quality standards. For comprehensive sourcing guidance, see our Retatrutide Buying Guide. For deeper coverage of the compound's mechanism, see How Does Retatrutide Work? For comparative context, see Retatrutide vs Other Research Peptides.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.

Back to blog